Pulsatile LHRH therapy for induction of ovulation in patients with hyperprolactinaemia and bromocriptine intolerance

Mechanism of anovulation in hyperprolactinemic amenorrhea determined by pulsatile gonadotropin-releasing hormone injection combined with human chorionic gonadotropin

OBJECTIVE

To clarify the mechanism of anovulation in hyperprolactinemic anovulatory women by subcutaneous (SC) pulsatile GnRH injection.

DESIGN

Prospective clinical study.

SETTING

Studies were made on at the Department of Obstetrics and Gynecology, the University of Tokushima, School of Medicine.

PATIENTS

Six hyperprolactinemic (group 1) and 7 normoprolactinemic (group 2) anovulatory patients were studied.

INTERVENTIONS

After examinations of pulsatile secretion of LH, the GnRH test, thyrotropin-releasing hormone test and estrogen test, pulsatile GnRH treatment (20 micrograms/2 hours SC) was performed. Two protocols were tested on each patient. In the non-hCG protocol, GnRH treatment was continued until ovulation. In the hCG protocol, 5,000 IU of hCG was injected to induce ovulation when follicles were fully mature.

MAIN OUTCOME MEASURE

The rates of follicular maturation and ovulation, serum E2 and P in the two groups.

RESULTS

Pulsatile LH secretion was impaired in both groups. LH release 48 hours after estrogen injection was impaired in group 1 but not in group 2. Follicles matured on pulsatile GnRH treatment in all cycles in both groups. However, with the non-hCG protocol, ovulation occurred in only 17% of group 1, but in 89% of group 2. With the hCG protocol ovulation occurred in all cycles in both groups.

CONCLUSIONS

The main cause of anovulation is impaired gonadotropin pulsatility and derangement of the estrogen-positive feedback effect on LH secretion in hyperprolactinemic patients, their ovarian response to gonadotropin being well maintained. Subcutaneous pulsatile GnRH therapy combined with hCG can be used as an alternative to bromocriptine treatment for induction of ovulation in these patients.